中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2011, Vol. 46 Issue (20) :1541-1545    DOI:
���� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << | >>
CYP3A5�����̬�Զ��ٴ�ҩ������ѧӰ����о���չ
��ޣ���漣������죬��ܿ*
�Ͼ���ѧҽѧԺ������¥ҽԺҩѧ�����Ͼ� 210008

Download: PDF (654KB)   HTML (0KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� ����ϸ��ɫ��P450 3A5�����̬�Զ��ٴ�ҩ������ѧӰ����о���չ������ ���������ɡ��ܽᷢ������ס���������� ҩ�������ѧͨ���о�������ˮƽ�����������̬�����ٴ�ҩ������ѧ��ҩ�ﶾ�Ե�����ԣ�����ҩ�����Ч�ԺͰ�ȫ�ԣ����ٲ�����Ӧ������ܵ��㷺�о���ȡ������Ҫ�Ľ�չ��ϸ��ɫ��P450 3A5������Ŵ���̬�Դ������Եĸ�����죬�Բ�ͬ�����ҩ���������úͲ�����Ӧ��ҩ��Ķ��Բ�����ҪӰ�죬��������弰������ͬһ�����л������ͬ��ԭ��֮һ��Ŀǰ�Ըû����̬�����ٴ�ҩ������ѧ���о���Ҫ�����ڴ������࿹���ء�����θ����ҩ�����μ��β�����ҩ������Ѫ֬ҩ���򾲴��߼�������ҩ�����ߵ��ڼ���ҩ�Լ�����ҩ�
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
�ؼ����� CYP3A5����   �����̬��   �ٴ�������ҩ   ҩ�������ѧ     
Abstract��
Keywords��   
�ո�����: 2011-11-11;
���ñ���:   
.CYP3A5�����̬�Զ��ٴ�ҩ������ѧӰ����о���չ[J]  �й�ҩѧ��־, 2011,V46(20): 1541-1545
.[J]  Chinese Pharmaceutical Journal, 2011,V46(20): 1541-1545
��
[1] RUF H H�� WENDE P�� ULLRICH V. Models for ferric cytochrome P450. Characterization of hemin mercaptide complexes by electronic and ESR spectra[J]. J Inorg Biochem��1979��11(3)�� 189-204. [2] KLINGENBERG M. Pigments of rat liver microsomes[J]. Arch Biochem Biophys��1958��75(2)�� 376-386. [3] RENDIC S. Summary of information on human CYP enzymes�� human P450 metabolism data[J]. Drug Metab Rev��2002��34(1-2)�� 83-448. [4] WILLIAMS J A�� RING B J�� CANTRELL V E�� et al. Comparative metabolic capabilities of CYP3A4�� CYP3A5�� and CYP3A7[J]. Drug Metab Dispos��2002��30(8)�� 883-891. [5] LIN Y S�� DOWLING A L�� QUIGLEY S D�� et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism[J]. Mol Pharmacol��2002��62(1)�� 162-172. [6] JOUNAIDI Y�� HYRAILLES V�� GERVOT L�� et al. Detection of CYP3A5 allelic variant�� a candidate for the polymorphic expression of the protein[J]. Biochem Biophys Res Commun��1996��221(2)�� 466-470. [7] XIE H G�� WOOD A J�� KIM R B�� et al. Genetic variability in CYP3A5 and its possible consequences[J]. Pharmacogenomics��2004��5(3)�� 243-272. [8] BUSI F�� CRESTEIL T. CYP3A5 mRNA degradation by nonsense-mediated mRNA decay[J]. Mol Pharmacol��2005��68(3)�� 808-815. [9] LANGAEE T Y�� GONG Y�� YARANDI H N�� et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil[J]. Clin Pharmacol Ther��2007��81(3)�� 386-391. [10] LIU L�� YANG L�� ZHANG Y C�� et al. Polymorphisms of drug-metabolizing enzymes genes in a Han Chinese population[J]. Natl Med J China(�л�ҽѧ��־)��2009��89(38)�� 2675-2681. [11] KUEHL P�� ZHANG J�� LIN Y�� et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of po1ymorphic CYP3A5 expression[J]. Nat Genet��2001��27(4)�� 383-391. [12] CHU X M�� GUO L Q�� HUANG C L. Effects of CYP3A5 and MDR1 genetic polymorphism on azithromycin pharmacokinetics in Chinese healthy volunteers[J]. J Chin Pharm Univ(�й�ҩ�ƴ�ѧѧ��)��2007��38(2)�� 167-171. [13] CHU X M�� CAO X M�� NI L�� et al. Combined effect of CYP3A5 and multidrug resistance gene 1 genetic variations on pharmacokinetics of clarithromycin[J]. Chin J Clin Pharmacol(�й��ٴ�ҩ��ѧ��־)��2009��25(5)�� 412-417. [14] MIURA M�� INOUE K�� SATOH S�� et al. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients[J]. Clin Drug Investig��2007��27(4)�� 251-258. [15] SUGIMOTO K�� UNO T�� TATEISHI T. Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs[J]. Eur J Clin Pharmacol��2008��64(6)�� 583-587. [16] LI Y�� ZHANG W�� GUO D�� et al. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes[J]. Clin Chim Acta��2008��391(1-2)�� 60-67. [17] FANG Z X�� LI D K�� YANG J�� et al. Clinical analysis of treating chronic hepatitis B with bicycolol[J]. World J Infect(�����Ⱦ��־)��2006��6(1)�� 67-69. [18] WANG R L�� YE X G�� YE L K. Effect of CYP3A5 genetic polymorphism on the response to bicyclol in patients with chronic hepatitis B[J]. Chin J New Drugs(�й���ҩ��־)��2008��17(4)�� 329-332. [19] KIM K A�� PARK P W�� LEE O J�� et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects[J]. J Clin Pharmacol��2007��47(1)�� 87-93. [20] KIVISTO K T�� NIEMI M�� SCHAEFFELER E�� et al. Lipid-lowering respones to statins is affected by CYP3A5 polymorphism[J]. Pharmacogenetics��2004��14(8)�� 523-525. [21] PARK J Y�� KIM K A�� PARK P W�� et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects[J]. Clin Pharmacol Ther��2006��79(4)�� 590-599. [22] HE P�� COURT M H�� GREENBLATT D J�� et al. Factors influencing midazolam hydroxylation activity in human liver microsomes[J]. Drug Metab Dispos��2006��34(7)�� 1198-1207. [23] EMOTO C�� IWASAKI K. Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1��-hydroxylation[J]. Xenobiotica��2007��37(6)�� 592-603. [24] HESSELINK D A�� VAN SCHAIK R H�� VAN DER HEIDEN I P�� et al. Genetic polymorphisms of the CYP3A4�� CYP3A5�� and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus[J]. Clin Pharmacol Ther��2003��74(3)�� 245-254. [25] ANGLICHEAU D�� THERVET E�� ETIENNE I�� et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation[J]. Clin Pharmacol Ther��2004��75(5)�� 422-433. [26] HU Y F�� QIU W�� LIU Z Q�� et al. Effects of genetic polymorphisms of CYP3A4�� CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation[J]. Clin Exp Pharmacol Physiol��2006��33(11)�� 1093-1098. [27] WANG H P�� MAO P�� XIE J J�� et al. Influence of CYP3A5 polymorphism on cyclosporin A concentration in the peripheral blood of hemopoietic stem cell transplant recipients[J]. Chin J Organ Transplant(�л�������ֲ��־)��2005��26(4)�� 207-209. [28] YU S F�� WU L H�� JING J�� et al. Influence of genetic polymorphism of donor CYP3A5 on FK506 individual dosage regimen in liver transplantation recipients [J]. Chin Pharm J (�й�ҩѧ��־)��2007��42(4)�� 314-317. [29] JIN Z�� ZHANG W X�� CHEN B�� et al. Effect of CYP3A5 and MDR1 gene polymorphism on concentration/dose ratios of tacrolimus in Chinese liver transplant patients[J]. Chin Pharm J (�й�ҩѧ��־)��2008��43(9)�� 649-653. [30] KATSAKIORI P F�� PAPAPETROU E P�� SAKELLAROPOULOS G C�� et al. Factors affecting the long-term response to tacrolimus in renal transplant patients�� Pharmacokinetic and pharmacogenetic approach[J]. Int J Med Sci��2010��7(2)�� 94-100. [31] DJEBLI N�� ROUSSEAU A�� HOIZEY G�� et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients[J]. Clin Pharmacokinet��2006��45(11)�� 1135-1148. [32] LUKAS J C�� CALVO R�� ZOGRAFIDIS A�� et al. Simulation of sirolimus exposures and population variability immediately post renal transplantation�� importance of the patient��s CYP3A5 genotype in tailoring treatment[J]. Biopharm Drug Dispos��2010��31(2-3)�� 129-137. [33] PARK P W�� SEO Y H�� AHN J Y�� et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients[J]. J Clin Pharm Ther��2009��34(5)�� 569-574. [34] JACQUES T�� CHANTAL P�� V�bRONIQUE M. Understanding clopidogrel efficacy in the presence of cytochrome P450 polymorphism[J]. CMAJ��2006��174(12)�� 1715. [35] KIM K A�� PARK P W�� PARK J Y. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects[J]. Eur J Clin Pharmacol��2008��64(6)�� 589-597. [36] YOO H D�� CHO H Y�� LEE Y B. Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5�� CYP2C19 and ABCB1[J]. Br J Clin Pharmacol��2010��69(1)�� 27-37. [37] KIM K A�� PARK P W�� LEE O J�� et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects[J]. Clin Pharmacol Ther��2006��80(6)�� 646-656. [38] YAMAMOTO T�� KUBOTA T�� OZEKI T�� et al. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem[J]. Clin Chim Acta��2005��362(1-2)�� 147-154. [39] ZHAO Y�� ZHAI D�� HE H�� et al. Effects of CYP3A5�� MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort[J]. Eur J Clin Pharmacol��2009��65(6)�� 579-584.
[1] ������ ��÷ ����Ӣ.�ຣ��������ȺCYP2C19�����̬���о�[J]. �й�ҩѧ��־, 2012,47(7): 539-542
[2] ��ٻ ���� ��ӱ ��һ�� .ת�˵��׻����̬��������ͪ�ֲ���������о�[J]. �й�ҩѧ��־, 2012,47(6): 454-457
[3] ���� ���� ����ͬ ���� ����� ����Ƽ.�й���ȺSTX4�����̬�ԶԻ�����Ӧ�ü�����Ӱ��[J]. �й�ҩѧ��־, 2011,46(9): 691-694
[4] ��� ¬����.�����̬�Զ�������ֲ���������Ƽ���ЧӰ����о���չ[J]. �й�ҩѧ��־, 2011,46(8): 561-564
[5] ף�� ��΢ ��ΰ�� ����Ң ����.�й�������Ⱥ������ҩ�������ѧ����Ԥ�⹫ʽ�Ƚ�[J]. �й�ҩѧ��־, 2011,46(24): 1929-1934
[6] л�� �κ��� ���컪 ��˳�� ̷����.CYP3A5*3��MDR1 G2677T/A�����̬�Զ�����ֲ���߻�����AѪҩŨ�ȼ���Ч��Ӱ��[J]. �й�ҩѧ��־, 2011,46(20): 1591-1596
[7] Ϳ���� ���Ҽ� ��˼Դ ʯ���� ����Ƽ ���� �����.�ȶ�������л�������ת����1��ϸ��ģ�͹���[J]. �й�ҩѧ��־, 2011,46(20): 1546-1551
[8] ������ ���� ���� �Ų� ���.����CYP3A5��MDR1�����̬�������ֲ������������Ī˾�ĸ��廯��ҩ������о�[J]. �й�ҩѧ��־, 2011,46(17): 1366-1369
[9] ����Զ л�� �κ���.������˥��ҩ�������ѧ�о���չ[J]. �й�ҩѧ��־, 2011,46(11): 804-808
[10] ����Ƽ ���� ���� ���� �ܺ��.����������ת����1��ҩ��������о���չ[J]. �й�ҩѧ��־, 2011,46(11): 801-803
[11] ��ٻ ���� ��ӱ ������ ��һ��.���ٰ���ҩ����BCRP��λ�������й����彡����Ⱥ�еķֲ�[J]. �й�ҩѧ��־, 2011,46(10): 771-773
[12] ���� �Զ��� ��ȫ�� ������ ������ ������ Ԭ����.MDR1�����̬�ԶԸ��ƻ��߷�̫�ᾲ����ʹҩЧѧ��Ӱ��[J]. �й�ҩѧ��־, 2010,45(5): 379-380
[13] ����Ƽ ÷�� ����ΰ ���� ��ޱ.CYP2C9��VKORC1�����̬�ԶԻ����ּ����Ϳ���Ч����Ӱ��[J]. �й�ҩѧ��־, 2010,45(21): 1628-1633
[14] �ƻ��� ������ ����.MDR1G2677T/A�����̬�ԶԻ�����ҩ���л����ѧ��ҩЧѧӰ���ϵͳ����[J]. �й�ҩѧ��־, 2010,45(2): 140-143
[15] ����ο �ź��� ����÷ ������c ������ ��Э��.��������ˮ��ø1�����̬�ԶԻ����ּ���Ӱ����о�[J]. �й�ҩѧ��־, 2010,45(19): 1488-1491
Copyright 2010 by �й�ҩѧ��־